Vidhu Menon, APRN
Nurse Practitioner · Nashua, NHNPI 1619441946
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 51.4% of the total. Among nurse practitioner clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $28.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- AbbVie$885
- Takeda Pharmaceuticals U.S.A., Inc.$37
- Axsome Therapeutics, Inc.$32
What the payments were for
- Food & beverage$1,91598%
- Education$472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $1,008 |
| AbbVie | 41 | $885 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Axsome Therapeutics, Inc. | 1 | $32 |
How this compares
$1,962 in reported general payments places this provider in the 95th percentile of 714 nurse practitioner providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 20 | $310 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 20 | $148 |
| Bupropion XlBupropion Hcl | 14 | $120 |
| Lorazepam | 15 | $60 |
| Clonazepam | 11 | $39 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in Nashua
- Jennifer GriffinNashua$5K
- Dawne HillsgroveNashua$4K
- Elise LoiselleNashua$4K
- Doreen CawleyNashua$4K
- Krista RadfordNashua$3K
- Cynthia CahoonNashua$912
- Jessica St JeanPelham$302K
- Michael RobustelliSomersworth$17K
- Denise McGrathLebanon$7K
- Lisa WilliamsBedford$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.